Dr. James Stocks, M.D.
What this data tells you about Dr. Stocks
Dr. James Stocks is an urology physician in Cypress, TX, with 14 years in practice. Based on federal Medicare data, Dr. Stocks performed 47,428 Medicare services across 2,926 unique beneficiaries.
Between the years covered by Open Payments, Dr. Stocks received a total of $5,783 from 37 pharmaceutical and/or device companies across 187 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Stocks is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Testosterone injection | 37,328 | $0 | $0 |
| Infectious disease DNA/RNA test | 3,094 | $34 | $68 |
| Identification of organisms by genetic analysis, amplified probe technique | 1,596 | $34 | $88 |
| Urinalysis, manual | 761 | $3 | $11 |
| Office visit, established patient (30-39 min) | 746 | $102 | $395 |
| Yeast/candida DNA test | 716 | $34 | $81 |
| Office visit, established patient (20-29 min) | 664 | $64 | $257 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 399 | $68 | $175 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 351 | $34 | $81 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 349 | $34 | $77 |
| Bladder ultrasound after voiding | 297 | $8 | $38 |
| Drug injection, under skin or into muscle | 252 | $11 | $73 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 141 | $34 | $87 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 137 | $34 | $87 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 133 | $34 | $88 |
| Hospital follow-up visit, moderate complexity | 119 | $63 | $238 |
| New patient office visit (45-59 min) | 103 | $128 | $516 |
| Diagnostic exam of bladder and urethra using an endoscope | 61 | $192 | $718 |
| Initial hospital admission, moderate complexity | 61 | $104 | $400 |
| Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | 47 | $629 | $2,383 |
| New patient office visit (30-44 min) | 34 | $63 | $323 |
| Complicated insertion of bladder tube | 24 | $118 | $458 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 15 | $538 | $4,434 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
5.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Stocks is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Stocks experienced with testosterone injection?
Does Dr. Stocks receive payments from pharmaceutical companies?
How do Dr. Stocks's costs compare to other urology physicians in Cypress?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology